Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 40 | 2023 | 21188 | 1.040 |
Why?
|
| Comprehensive Health Care | 2 | 2016 | 123 | 0.610 |
Why?
|
| Mastectomy | 7 | 2018 | 1850 | 0.600 |
Why?
|
| Oncology Service, Hospital | 1 | 2016 | 57 | 0.510 |
Why?
|
| Patient Care Team | 2 | 2016 | 2528 | 0.430 |
Why?
|
| Paclitaxel | 10 | 2021 | 1735 | 0.410 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2018 | 933 | 0.390 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2018 | 1093 | 0.390 |
Why?
|
| Mammaplasty | 3 | 2016 | 1263 | 0.380 |
Why?
|
| Environment Design | 1 | 2013 | 174 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2021 | 11886 | 0.370 |
Why?
|
| Inservice Training | 1 | 2013 | 375 | 0.350 |
Why?
|
| Epothilones | 5 | 2013 | 42 | 0.350 |
Why?
|
| Biomedical Technology | 1 | 2012 | 210 | 0.340 |
Why?
|
| Pharmacoepidemiology | 1 | 2012 | 351 | 0.320 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2016 | 631 | 0.280 |
Why?
|
| Critical Pathways | 2 | 2022 | 476 | 0.280 |
Why?
|
| Referral and Consultation | 5 | 2018 | 3628 | 0.260 |
Why?
|
| Neoplasm Staging | 8 | 2018 | 11262 | 0.250 |
Why?
|
| Medical Oncology | 3 | 2022 | 2350 | 0.240 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2024 | 17 | 0.230 |
Why?
|
| Drug Costs | 1 | 2012 | 1198 | 0.230 |
Why?
|
| Music Therapy | 1 | 2006 | 111 | 0.230 |
Why?
|
| Fluorouracil | 5 | 2024 | 1655 | 0.220 |
Why?
|
| Communication | 1 | 2016 | 3908 | 0.200 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 9549 | 0.200 |
Why?
|
| Deoxycytidine | 4 | 2012 | 888 | 0.190 |
Why?
|
| Neoplasms | 8 | 2022 | 22389 | 0.190 |
Why?
|
| Taxoids | 4 | 2008 | 668 | 0.190 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 3538 | 0.190 |
Why?
|
| Mastectomy, Segmental | 2 | 2018 | 960 | 0.180 |
Why?
|
| Isoquinolines | 1 | 2001 | 354 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2018 | 3554 | 0.170 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2018 | 716 | 0.170 |
Why?
|
| Neutropenia | 3 | 2016 | 893 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2024 | 647 | 0.160 |
Why?
|
| Antineoplastic Agents | 8 | 2012 | 13698 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2016 | 4879 | 0.160 |
Why?
|
| Tegafur | 1 | 1998 | 40 | 0.160 |
Why?
|
| Quality of Health Care | 1 | 2014 | 4339 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 9080 | 0.150 |
Why?
|
| Stress, Physiological | 1 | 2006 | 1408 | 0.150 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 682 | 0.150 |
Why?
|
| Uracil | 1 | 1998 | 210 | 0.140 |
Why?
|
| Female | 44 | 2024 | 397515 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2016 | 622 | 0.130 |
Why?
|
| Receptors, Estrogen | 3 | 2023 | 2252 | 0.130 |
Why?
|
| Anthracyclines | 2 | 2008 | 286 | 0.130 |
Why?
|
| Receptors, Progesterone | 2 | 2018 | 1159 | 0.120 |
Why?
|
| Cancer Care Facilities | 2 | 2018 | 428 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2017 | 504 | 0.110 |
Why?
|
| Adult | 27 | 2021 | 223851 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 592 | 0.110 |
Why?
|
| Middle Aged | 29 | 2021 | 223737 | 0.110 |
Why?
|
| Phlebotomy | 1 | 2014 | 138 | 0.110 |
Why?
|
| Humans | 50 | 2024 | 768970 | 0.110 |
Why?
|
| Radiology | 2 | 2018 | 2104 | 0.110 |
Why?
|
| Aged | 25 | 2023 | 171786 | 0.100 |
Why?
|
| Vinblastine | 3 | 2003 | 487 | 0.100 |
Why?
|
| Receptor, erbB-2 | 6 | 2021 | 2606 | 0.100 |
Why?
|
| Neoplasm Metastasis | 7 | 2021 | 4926 | 0.100 |
Why?
|
| Trust | 1 | 2016 | 532 | 0.100 |
Why?
|
| Tubulin Modulators | 1 | 2012 | 106 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3629 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2021 | 2029 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2006 | 4530 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2016 | 1481 | 0.090 |
Why?
|
| Attitude to Health | 1 | 2019 | 2025 | 0.090 |
Why?
|
| Potassium | 1 | 2014 | 1315 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2010 | 5342 | 0.080 |
Why?
|
| Quality Improvement | 2 | 2016 | 3860 | 0.080 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2004 | 737 | 0.080 |
Why?
|
| Mammography | 2 | 2018 | 2434 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2018 | 2909 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 9442 | 0.070 |
Why?
|
| Quality of Life | 3 | 2006 | 13510 | 0.070 |
Why?
|
| Reoperation | 1 | 2018 | 4342 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 937 | 0.070 |
Why?
|
| Doxorubicin | 6 | 2016 | 2234 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2018 | 41808 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 941 | 0.070 |
Why?
|
| Aged, 80 and over | 8 | 2018 | 59739 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2019 | 8748 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2018 | 3591 | 0.060 |
Why?
|
| Boston | 3 | 2014 | 9377 | 0.060 |
Why?
|
| Paroxetine | 1 | 2005 | 181 | 0.060 |
Why?
|
| Genital Neoplasms, Female | 1 | 2010 | 538 | 0.060 |
Why?
|
| Cyclophosphamide | 5 | 2016 | 2227 | 0.060 |
Why?
|
| Integrative Medicine | 1 | 2006 | 87 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 7460 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2005 | 349 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2019 | 3463 | 0.050 |
Why?
|
| Drug Administration Schedule | 5 | 2018 | 4862 | 0.050 |
Why?
|
| Young Adult | 5 | 2018 | 60131 | 0.050 |
Why?
|
| Hot Flashes | 1 | 2005 | 330 | 0.050 |
Why?
|
| New England | 1 | 2006 | 1058 | 0.050 |
Why?
|
| Registries | 1 | 2018 | 8384 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 3411 | 0.050 |
Why?
|
| Time Factors | 6 | 2018 | 40261 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2013 | 3143 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8664 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2005 | 718 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 6 | 2003 | 9264 | 0.040 |
Why?
|
| Survivors | 1 | 2010 | 2383 | 0.040 |
Why?
|
| Alkylating Agents | 1 | 2000 | 132 | 0.040 |
Why?
|
| Neuroendocrine Tumors | 1 | 2005 | 657 | 0.040 |
Why?
|
| Mesna | 1 | 1998 | 62 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2005 | 1738 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2004 | 2916 | 0.040 |
Why?
|
| Feedback | 1 | 2022 | 799 | 0.040 |
Why?
|
| Adolescent | 3 | 2015 | 89244 | 0.040 |
Why?
|
| Prognosis | 2 | 2015 | 30046 | 0.040 |
Why?
|
| Ifosfamide | 1 | 1998 | 233 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2010 | 3270 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 39394 | 0.030 |
Why?
|
| Survival Rate | 1 | 2010 | 12873 | 0.030 |
Why?
|
| Stem Cell Factor | 1 | 1996 | 194 | 0.030 |
Why?
|
| Obesity | 1 | 2018 | 13091 | 0.030 |
Why?
|
| Anemia | 1 | 2005 | 1517 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 24333 | 0.030 |
Why?
|
| Nitriles | 1 | 2021 | 990 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 2004 | 3473 | 0.030 |
Why?
|
| Mastocytosis | 1 | 1996 | 150 | 0.030 |
Why?
|
| Retrospective Studies | 6 | 2023 | 81903 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 2003 | 1258 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2019 | 904 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2005 | 3205 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2018 | 2932 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 1019 | 0.030 |
Why?
|
| Medical Records | 1 | 2018 | 1411 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 5375 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2019 | 5323 | 0.030 |
Why?
|
| Observer Variation | 1 | 2018 | 2623 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1913 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2001 | 3726 | 0.020 |
Why?
|
| Decision Making | 1 | 2005 | 3953 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2000 | 5716 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 640 | 0.020 |
Why?
|
| Mast Cells | 1 | 1996 | 1406 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 3048 | 0.020 |
Why?
|
| Consensus | 1 | 2018 | 3214 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 6856 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2784 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 878 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 899 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 8055 | 0.020 |
Why?
|
| Treatment Outcome | 6 | 2013 | 65480 | 0.020 |
Why?
|
| Tocopherols | 1 | 2005 | 44 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 2543 | 0.020 |
Why?
|
| Filgrastim | 1 | 2005 | 131 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 6982 | 0.020 |
Why?
|
| Survival Analysis | 3 | 2003 | 10115 | 0.020 |
Why?
|
| Radiation Pneumonitis | 1 | 2005 | 100 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 10765 | 0.010 |
Why?
|
| Disease Management | 1 | 2015 | 2537 | 0.010 |
Why?
|
| Cisplatin | 2 | 2001 | 1661 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2006 | 54962 | 0.010 |
Why?
|
| Male | 7 | 2024 | 365203 | 0.010 |
Why?
|
| Quinazolines | 1 | 2010 | 1373 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2010 | 1277 | 0.010 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2004 | 241 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2005 | 613 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2005 | 410 | 0.010 |
Why?
|
| Carotenoids | 1 | 2005 | 620 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6547 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 2005 | 740 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 2000 | 6131 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18435 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 9213 | 0.010 |
Why?
|
| Premenopause | 1 | 2005 | 1039 | 0.010 |
Why?
|
| Risk Factors | 3 | 2018 | 74976 | 0.010 |
Why?
|
| Placebos | 1 | 2005 | 1667 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 70 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1998 | 4919 | 0.010 |
Why?
|
| Cell Division | 2 | 1999 | 4478 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 2005 | 575 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 1793 | 0.010 |
Why?
|
| Incidence | 1 | 2018 | 21547 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 2000 | 129 | 0.010 |
Why?
|
| Carmustine | 1 | 2000 | 137 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2005 | 1197 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2003 | 8559 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 2108 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2016 | 22296 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2005 | 2921 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2231 | 0.010 |
Why?
|
| Disease Progression | 2 | 2007 | 13674 | 0.010 |
Why?
|
| Melphalan | 1 | 2000 | 421 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 1812 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 793 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 12562 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2012 | 8094 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 6512 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 3629 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2005 | 2008 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20776 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2005 | 2701 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2000 | 1231 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 5906 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 15951 | 0.010 |
Why?
|
| Algorithms | 2 | 2005 | 14201 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1999 | 1599 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 13594 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12095 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 12467 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 36854 | 0.010 |
Why?
|
| Spleen | 1 | 1996 | 2294 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2003 | 2819 | 0.010 |
Why?
|
| Cell Survival | 1 | 2000 | 5793 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1996 | 1855 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2001 | 2057 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 10400 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 20245 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1996 | 3659 | 0.000 |
Why?
|
| Recurrence | 1 | 1999 | 8513 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 10276 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 15471 | 0.000 |
Why?
|
| Models, Biological | 1 | 1999 | 9499 | 0.000 |
Why?
|
| Skin | 1 | 1996 | 4506 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1996 | 11684 | 0.000 |
Why?
|
| Mice | 1 | 2000 | 82072 | 0.000 |
Why?
|
| Animals | 1 | 2000 | 169335 | 0.000 |
Why?
|
Concepts
(222)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(68)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_